Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis

Ibrutinib Could Suppress CA-125 in Ovarian Cancer: A Hypothesis

Ibrutinib is a small-molecule inhibitor of Bruton’s tyrosine kinase, an enzyme central in B cell development. It is indicated as a therapy for certain hematological diseases such as chronic lymphocytic leukemia (CLL), but also exerts off-target effects on several receptors and kinases. In this paper...

Full description

Bibliographic Details
Main Authors:	Julian Matthias Metzler, Daniel Fink, Patrick Imesch
Format:	Article
Language:	English
Published:	MDPI AG 2021-12-01
Series:	Applied Sciences
Subjects:	ibrutinib Bruton’s tyrosine kinase Btk kinase inhibitor ovarian cancer gynecological oncology
Online Access:	https://www.mdpi.com/2076-3417/11/1/222

Similar Items

Ibrutinib in B-cell lymphoma: single fighter might be enough?
by: Chao Xue, et al.
Published: (2020-09-01)

Evaluating ibrutinib in the treatment of symptomatic Waldenstrom’s macroglobulinemia
by: Papanota AM, et al.
Published: (2019-08-01)

Bruton's Tyrosine Kinase Inhibition Attenuates the Cardiac Dysfunction Caused by Cecal Ligation and Puncture in Mice
by: Caroline E. O'Riordan, et al.
Published: (2019-09-01)

Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
by: Bartosz Puła, et al.
Published: (2019-11-01)

Btk inhibitor ibrutinib reduces inflammatory myeloid cell responses in the lung during murine pneumococcal pneumonia
by: Alexander P. de Porto, et al.
Published: (2019-01-01)

Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer
by: Zhu Z, et al.
Published: (2020-05-01)

Role of Bruton’s Tyrosine Kinase in Stage III Colorectal Cancer
by: Debora Basile, et al.
Published: (2019-06-01)

Btk Inhibitors: A Medicinal Chemistry and Drug Delivery Perspective
by: Chiara Brullo, et al.
Published: (2021-07-01)

Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia
by: Benjamin Arthurs, MD, et al.
Published: (2017-01-01)

Emergence of overt myeloma in a patient with chronic lymphocytic leukemia on ibrutinib therapy
by: Ayad M. Al‐Katib, et al.
Published: (2020-09-01)

X-Linked Immunodeficient Mice With No Functional Bruton's Tyrosine Kinase Are Protected From Sepsis-Induced Multiple Organ Failure
by: Caroline E. O'Riordan, et al.
Published: (2020-10-01)

Novel Indications for Bruton’s Tyrosine Kinase Inhibitors, beyond Hematological Malignancies
by: Robert Campbell, et al.
Published: (2018-03-01)

Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells
by: Yamit Shorer Arbel, et al.
Published: (2021-05-01)

Chronic Hepatitis E Virus Infection during Lymphoplasmacytic Lymphoma and Ibrutinib Treatment
by: Bernhard Schlevogt, et al.
Published: (2019-08-01)

Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model
by: Yaya Chu, et al.
Published: (2019-01-01)

Bruton’s Tyrosine Kinase Inhibitors: A New Therapeutic Target for the Treatment of SLE?
by: Lorenzo-Vizcaya A, et al.
Published: (2020-06-01)

Waldenström macroglobulinemia: biology, genetics, and therapy
by: Paludo J, et al.
Published: (2016-07-01)

Bruton’s Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib Counteract Anthracycline Resistance in Cancer Cells Expressing AKR1C3
by: Anselm Morell, et al.
Published: (2020-12-01)

Specific Expression of a New Bruton Tyrosine Kinase Isoform (p65BTK) in the Glioblastoma Gemistocytic Histotype
by: Luca Sala, et al.
Published: (2019-01-01)

Molecular Drug Discovery of Single Ginsenoside Compounds as a Potent Bruton’s Tyrosine Kinase Inhibitor
by: Keun Woo Lee, et al.
Published: (2020-04-01)

Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
by: Sklavenitis-Pistofidis R., et al.
Published: (2017-06-01)

Bruton Tyrosine Kinase Inhibition and Its Role as an Emerging Treatment in Pemphigus
by: Aikaterini Patsatsi, et al.
Published: (2021-08-01)

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review
by: Zemene Demelash Kifle
Published: (2021-09-01)

The Diagnostic, Prognostic, and Therapeutic Utility of Molecular Testing in a Patient with Waldenstrom’s Macroglobulinemia
by: Collin K. Chin, et al.
Published: (2017-09-01)

Targeting Solid Tumors With BTK Inhibitors
by: Fatih M. Uckun, et al.
Published: (2021-04-01)

Bruton’s Tyrosine Kinase Targeting in Multiple Myeloma
by: Max Von Suskil, et al.
Published: (2021-05-01)

Reining in BTK: Interdomain Interactions and Their Importance in the Regulatory Control of BTK
by: Lauren E. Kueffer, et al.
Published: (2021-06-01)

A Case of Hypophosphatemiawith Increased Urinary Excretion of Phosphorus Associated with Ibrutinib
by: Ewa M. Wysokinska, et al.
Published: (2016-04-01)

Cerebral aspergillosis and facial acneiform lesions following initiation of ibrutinib in a patient with chronic lymphocytic leukemia
by: Helbies Bedier, et al.
Published: (2021-01-01)

The role of second generation Bruton tyrosine kinase inhibitors in the treatment of chronic lymphocytic leukemia. Resolution
by: Irina V. Poddubnaya, et al.
Published: (2020-05-01)

Observations on the use of Bruton’s tyrosine kinase inhibitors in SAR-CoV-2 and cancer
by: Brooke Benner, et al.
Published: (2021-01-01)

Bruton’s Tyrosine Kinase-Mediated Signaling in Myeloid Cells Is Required for Protective Innate Immunity During Pneumococcal Pneumonia
by: Alexander P. de Porto, et al.
Published: (2021-09-01)

Non-Covalent BTK Inhibitors—The New BTKids on the Block for B-Cell Malignancies
by: Katharine L Lewis, et al.
Published: (2021-08-01)

Targeting Bruton’s Tyrosine Kinase in Inflammatory and Autoimmune Pathologies
by: Stefan F. H. Neys, et al.
Published: (2021-06-01)

The role of ibrutinib in COVID-19 hyperinflammation: A case report
by: Suzanne Maynard, et al.
Published: (2021-04-01)

Ex Vivo Mitochondrial Respiration Parallels Biochemical Response to Ibrutinib in CLL Cells
by: Subir Roy Chowdhury, et al.
Published: (2021-01-01)

Bruton’s Tyrosine Kinase: An Emerging Key Player in Innate Immunity
by: Alexander N. R. Weber, et al.
Published: (2017-11-01)

Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence
by: Andrei A. Petrenko, et al.
Published: (2021-08-01)

Targeting Bruton’s Tyrosine Kinase in CLL
by: Inhye E. Ahn, et al.
Published: (2021-06-01)

Highly selective inhibition of Bruton’s tyrosine kinase attenuates skin and brain disease in murine lupus
by: Samantha A. Chalmers, et al.
Published: (2018-01-01)